People affected by the lethal glioblastoma cancer only live for 12–18 months after diagnosis.

A global trial that began in 2007 has confirmed that a vaccine for the treatment of the most lethal brain cancer can give patients years of extended life.

---

Peterschreiber.media/iStock.

“This is a potent molecule that’s very exciting to us in terms of its potential for deployment against glioblastoma,” said Steve Kay, Ph.D., the senior author of the study.

By mushrooms…?

People like Nathan have found out first hand that they can. You may have also seen scientists and doctors talking about mycotherapy for serious chronic conditions like cancer and HIV. That’s because many conditions thought of as diseases really have the same cause– an immune system that was unbalanced and compromised by environmental factors or diet.

Certain foods we eat are inflammatory, they boost problematic cells in our body called TH2 cytokines, which cause inflammation, and these cells can cause allergic reactions, auto-immune conditions, and weaken the cancer-fighting TH1 cytokines. When the TH1 cytokines are weakened by inflammatory foods, cancer is allowed to thrive and grow and spread.

But our bodies naturally have the ability to fight diseases and cancers, that’s what our immune system’ does.

The cells responsible for finding and removing cancer in our body, the TH1 cytokines, do this amazingly– but inflammatory foods and environments shut them down and prevent these natural cells from doing their jobs and killing cancerous cells quickly.

The best way to help reverse this process is by eliminating inflammatory foods and using nature’s miracle– mushrooms.

Many mushrooms are immune stimulating and modulating. Mushrooms like the Shiaqga mushroom with a high concentration of beta-glucans help boost the immune systems and support effective T-cell activity.

Patient-specific modeling could help clinicians determine whether an individual’s brain aneurysm is at risk of bursting.

According to the researchers, these drugs may effectively prevent dementia in high-risk individuals with mild to moderate type 2 diabetes, and it may now be worthwhile to give them priority in future clinical trials to determine whether they can be repurposed.

Researchers have begun to investigate whether diabetes drugs could potentially help prevent or cure dementia since type 2 diabetes and dementia share several physiological patterns. However, the results have been inconsistent thus far.

The researchers compared the incidence of dementia in older adults with type 2 diabetes who were receiving either sulfonylurea or thiazolidinedione (TZD) with those receiving metformin alone in order to shed further light on this.

A mechanism has been discovered that regulates cellular levels of tau, a protein whose aberrant accumulation is at the root of tauopathies, a class of devastating neurodegenerative diseases.

The finding was discovered in the laboratory of Michel Cayouette, director of cellular neurobiology research at the Montreal Clinical Research Institute (IRCM) and a medical professor at the University of Montreal.

The research, which was recently published in the journal Science Advances, demonstrates how the protein known as ‘numb’ regulates intracellular tau levels, making numb a potential therapeutic agent for tauopathies.